Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Clemizole hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Clemizole hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy...
Data Insights
Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy...